Form 4: Erich Platzer Reports Aptose Biosciences Share Changes

Erich Platzer, former director of Aptose Biosciences Inc., has reported transactions involving common shares and stock options.

Summary

• Erich Platzer, previously a director at Aptose Biosciences Inc., has filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• The filing indicates a disposition of 1,122 common shares on June 30, 2026, at a price of $1.72 per share.
• This disposition was part of a business arrangement agreement where a subsidiary of Hammi Pharmaceuticals Co. Ltd. acquired all outstanding shares of Aptose Biosciences at C$2.41 per share.
• The conversion of the Canadian price to USD used an exchange rate of C$1.4 to US$1.00.
• The filing also details various stock options held by Platzer, including grants with exercise prices ranging from $0.66 to $7.08.
• These options have varying vesting schedules, with some vesting 50% on the first anniversary of the grant date and the remainder vesting annually thereafter.
• Adjustments to option prices and amounts are noted due to previous reverse stock splits (1:30 on 2/25/25 and 1:15 on 6/6/2023).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a completed acquisition and related insider transactions rather than new strategic initiatives or financial performance.

Positives

• The disposition of shares and options is part of a court-approved business arrangement, indicating a structured and potentially beneficial exit for shareholders.
• The acquisition by Hammi Pharmaceuticals Co. Ltd. at C$2.41 per share suggests a valuation that may be favorable to existing shareholders.

Negatives

• The filing reflects a disposition of securities by a former director, which could be interpreted as a reduction in insider confidence or a realization of gains.
• The significant number of stock options detailed, with exercise prices above the reported share disposition price, may indicate that many options are currently out-of-the-money.

Risks

• The company has undergone reverse stock splits, which can sometimes be a sign of financial distress or an attempt to meet exchange listing requirements.
• The acquisition by Hammi Pharmaceuticals Co. Ltd. implies a change in control and potential strategic shifts for Aptose Biosciences.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from management regarding future performance. It primarily reports past transactions.

Management Comments

• "Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share."
• "Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00."
• "Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date."
• "TOTAL OPTIONS AND OPTION EXERCISE PRICE SUBJECT TO ADJUSTMENT AS A RESULT OF THE ISSUER'S 1:30 REVERSE STOCK SPLIT ON 2/25/25 AND 1:15 REVERSE STOCK SPLIT ON 6/6/2023"

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The context of an acquisition by Hammi Pharmaceuticals suggests a significant event for Aptose Biosciences, potentially leading to delisting or integration into the acquiring entity's operations.

Management Changes

Legal Proceedings

• The disposition of shares was part of a "board, shareholder and court-approved business arrangement agreement" for the acquisition of the company.

Related Party Transactions

• The disposition of 1,122 common shares by Erich Platzer was part of a business arrangement with Hammi Pharmaceuticals Co. Ltd., a related party through the acquisition agreement.

Stakeholder Impact

• Shareholders: The acquisition by Hammi Pharmaceuticals at C$2.41 per share provides a liquidity event for shareholders.
• Employees: Employees of Aptose Biosciences may experience changes in employment status or company structure due to the acquisition.
• Management: Former director Erich Platzer has reported transactions related to the acquisition.

Next Steps

• The acquisition by Hammi Pharmaceuticals Co. Ltd. is a completed event, implying integration and potential changes to Aptose Biosciences' operational status.
• Further filings may be expected regarding the post-acquisition status of Aptose Biosciences and its securities.

Key Dates

Recommendation

The filing reports a completed acquisition and insider transactions, which are largely historical events. While the acquisition price provides a benchmark, the future direction of the combined entity under Hammi Pharmaceuticals is not detailed, making a definitive buy or sell recommendation premature based solely on this Form 4.

Keywords

Form 4, SEC Filing, Aptose Biosciences, Erich Platzer, Stock Options, Beneficial Ownership, Insider Trading, Share Disposition, Hammi Pharmaceuticals, Reverse Stock Split